RockvilleOffice_0010c_pp-X3.jpg

James F. Barter, MD

Gynecologic Oncology, Gynecology, Gynecological Surgery

Undergraduate: Washington and Lee University
Medical School: University of Virginia School of Medicine (1977)
Internship: University of Kentucky Hospital (1979)
Residency: Duke University (1983)
Fellowship: University of Birmingham, Gynecologic Oncology (1986)
Board Certifications: Gynecologic Oncology, Gynecology
Languages: English

TopDocs+(2).jpg

To make an appointment:

Call (301) 770-4967


About Dr. Barter:

"I grew up in the Washington DC area and always wanted to be a doctor. My father was the OB-Gyn Chairperson at George Washington University and, when I started medical training, I would accompany him to the operating room. I went to college in Virginia and them Medical School at the University of Virginia. After 2 years of Internal Medicine , I went to Duke University for 4 years for Ob Gyn residency and then did my Gynecologic Oncology Fellowhsip at the University of Alabama in Birmingham. At that time, UAB had one of the highest surgical volume training programs in the United States ….

I am board certified in Gynecologic Oncology and Obstetrics/Gynecology, and practice Gynecologic Oncology at Holy Cross Hospital in Silver Spring, Maryland in the Washington, D.C. area. I am the Director of Gynecologic Oncology Research at Holy Cross, and have been in private practice for approximately 12 years. For the 16 years prior to that I was at Lombardi Cancer Center at Georgetown University. When I left Georgetown to enter private practice, I was a full professor. Currently, I have a very busy Gynecologic Oncology private practice personally doing approximately 800 surgical cases per year. Our educational service includes fellows from Walter Reed Army Hospital, residents from Howard University Medical Center, medical students from George Washington University and various other Medical Schools.  In the summer of 2014, I established an acting internship for fourth year medical students. I am a clinical professor of Gynecologic Oncology at the George Washington University Medical School. I very much enjoy trying to help patients out with various problems." 

Dr. Barter has been very involved in research - below are the list of trials that he has participated in:

Research Study Title

1. Serum Proteomics: For Detection of Ovarian Cancer Using the Correlogic Systems, Inc. Serum Pattern blood Test.

 

2. GOG–0218: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab in Patients With Ovarian Cancer

 

3. ChemoFx ®  PRO,  a post –market data collection study utilizing physician report outcomes

 

4. Bristol-Myers Squibb: A Phase III Open Label, Randomized Study of Ixabepilone Versus Paclitaxel Or Doxorubicin in Women with Advanced Endometrial Cancer.

 

5. GOG-0252: Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Ovarian Epithelial Cancer

 

6. Effectiveness of Radio-Frequency Surgical Detection System

 

7. Millennium Pharmaceuticals, Inc.: Randomized Phase 2 Study of an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Ovarian Cancer

 

8. GOG–0262: Phase III Trial of Every-3-weeks Paclitaxel vs. Dose Dense Weekly Paclitaxel in Combination with Caboplatin Plus Concurrent and Consolidation Bevacizumab in the Treatment of Epithelial Ovarian Cancer

 

9. A Randomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (Herceptin®) in Her2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma, Sponsor: Yale University School of Medicine

 

10. GOG 258: Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

 

11. EMR 200066_012( Serono) Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer

 

12. A Phase 1/2a, open-label, parallel, two-arm dose-escalation study to assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of BAX69 in subjects with refractory ovarian cancer with malignant ascites.

 

13. Forward1: a randomized, open label phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (imgn853) versus investigator’s choice of chemotherapy in women with folate receptor alpha positive advanced epithelial ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer.

 

14. PRIMA : A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

 

15. Phase II single arm trial with combination of Everolimus and Letrozole in treatment of platinum resistant relapse or refractory or persistent ovarian cancer/endometrial cancer

 

16. Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy

 

17. A Randomized, Open-Label, Multicenter, Phase 3  Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

 

18. Uterine surgery utilizing the FDA approved Pneumo-liner contained morcellation system

 

19. An open-label, randomized, phase 3 clinical trial of regn2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinumrefractory cervical carcinoma

 

20. A phase III, multicenter, randomized, study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly diagnosed stage iii or stage iv ovarian, fallopian tube, or primary peritoneal cancer

 

21. Tesaro – First : A randomized, double-blind, phase 3 comparison of platinum-based therapy with tsr-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer

Sponsor

Correlogic Systems, Inc

 

 

NCI/NIH Government sponsored

 

 

Precision Therapeutics, Incorporated

 

Bristol-Myers Squibb

 

 

NCI/NIH Government sponsored

 

RF Surgical Systems, Inc.

 

Millennium Pharmaceuticals, Inc

 

 

NCI/NIH Government sponsored

 

 

Yale University School of Medicine

 

 

 

NCI/NIH Government sponsored

 

 

EMD Serono Inc., One Technology Place, Rockland, MA 02370, USA

 

 

Baxalta US Inc.

 

 

 

ImmunoGen, Inc.

 

 

 

TESARO, Inc.

 

 

 

Novartis

 

 

AstraZeneca

 

 

 

 

Pfizer

 

 

 

 

PI Initiated

 

Regeneron

 

 

F. Hoffmann-La Roche Ltd

 

 

 

TESARO, Inc.

 

 

Activation at Holy Cross Hospital

April 2005

 

 

January 2008

 

 

October 2008

 

 

September 2009

 

 

November 2009

 

April 2010

 

4Qtr 2010

 

 

November 2010

 

 

 

December 2012

 

 

 

 

April 2013

 

 

October 2013

 

 

October 2015

 

 

 

May 2016

 

 

 

 

July  2016

 

 

 

July  2016

 

 

December 2016

 

 

 

 

April 2017

 

 

 

 

September 2017

 

October 2017

 

 

July 2018

 

 

 

July 2018

 

Locations:

 

Rockville

Tuesdays

6301 Executive Blvd
Rockville, MD 20852


Parking: FREE

 

Germantown

Fridays

12800 Middlebrook Rd, Suite 480
Germantown, MD 20874


Parking: FREE